ORUM
Orum Therapeutics, Inc., a biopharmaceutical company, engages in the research and development of pharmaceuticals for cancer and immune diseases. The company develops BMS-986497 (ORM-6151), which is in phase 1 clinical trial to treat acuta myeloid leukemia and high-risk myelodysplastic syndromes; ORM-1153, which is in preclinical trial to treat acuta myeloid leukemia and heme-onc; and ORM-1023, wh… Read more
ORUM (475830) - Total Assets
Latest total assets as of March 2025: ₩191.52 Billion KRW
Based on the latest financial reports, ORUM (475830) holds total assets worth ₩191.52 Billion KRW as of March 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
ORUM - Total Assets Trend (2022–2024)
This chart illustrates how ORUM’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
ORUM - Asset Composition Analysis
Current Asset Composition (December 2024)
ORUM's total assets of ₩191.52 Billion consist of 79.6% current assets and 20.4% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩19.70 Billion | 0.0% |
| Accounts Receivable | ₩2.44 Billion | 1.6% |
| Inventory | ₩0.00 | 0.0% |
| Property, Plant & Equipment | ₩30.61 Billion | 19.9% |
| Intangible Assets | ₩0.00 | 0.0% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2022–2024)
This chart illustrates how ORUM's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: ORUM's current assets represent 79.6% of total assets in 2024, an increase from 59.5% in 2022.
- Cash Position: Cash and equivalents constituted 0.0% of total assets in 2024, the same as 0.0% in 2022.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2022.
- Asset Diversification: The largest asset category is property, plant & equipment at 19.9% of total assets.
ORUM Competitors by Total Assets
Key competitors of ORUM based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
ORUM - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - ORUM generates 0.14x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - ORUM is currently not profitable relative to its asset base.
ORUM - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 28.33 | 22.03 | 22.03 |
| Quick Ratio | 28.33 | 22.03 | 22.03 |
| Cash Ratio | 1.31 | 5.21 | 5.21 |
| Working Capital | ₩155.02 Billion | ₩ 121.18 Billion | ₩ 121.18 Billion |
ORUM - Advanced Valuation Insights
This section examines the relationship between ORUM's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -4.9% |
| Total Assets | ₩153.84 Billion |
| Market Capitalization | $876.54K USD |
Valuation Analysis
Below Book Valuation: The market values ORUM's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: ORUM's assets decreased by 4.9% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for ORUM (2022–2024)
The table below shows the annual total assets of ORUM from 2022 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩153.84 Billion | -4.91% |
| 2023-12-31 | ₩161.78 Billion | +660.16% |
| 2022-12-31 | ₩21.28 Billion | -- |